NO975555L - Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein - Google Patents

Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein

Info

Publication number: NO975555L
Authority: NO; Norway
Prior art keywords: protein; vaccine; carrier; polysaccharidangite; free
Prior art date: 1995-06-07

Application number

NO975555A

Other languages

English (en)

Norwegian (no)

Other versions

NO975555D0 (no

Inventor

Moncef Mohamed Slaoui

Pierre Hauser

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1997-12-02

Publication date

1998-01-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO975555(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-23 Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en

1995-07-01 Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en

1995-12-15 Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en

1997-12-02 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

1997-12-02 Publication of NO975555D0 publication Critical patent/NO975555D0/no

1998-01-09 Publication of NO975555L publication Critical patent/NO975555L/no

Links

229960005486 vaccine Drugs 0.000 title abstract 7
102000014914 Carrier Proteins Human genes 0.000 title abstract 3
108010078791 Carrier Proteins Proteins 0.000 title abstract 3
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
150000004676 glycans Chemical class 0.000 abstract 2
229920001282 polysaccharide Polymers 0.000 abstract 2
239000005017 polysaccharide Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Virology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO975555A 1995-06-07 1997-12-02 Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein NO975555L (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US47263995A	1995-06-07	1995-06-07
GBGB9512827.8A GB9512827D0 (en)	1995-06-23	1995-06-23	Vaccines
GBGB9513443.3A GB9513443D0 (en)	1995-07-01	1995-07-01	Vaccines
GBGB9525657.4A GB9525657D0 (en)	1995-12-15	1995-12-15	Vaccines
PCT/EP1996/002436 WO1996040242A1 (en)	1995-06-07	1996-06-04	Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein

Publications (2)

Publication Number	Publication Date
NO975555D0 NO975555D0 (no)	1997-12-02
NO975555L true NO975555L (no)	1998-01-09

Family

ID=27451300

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO975555A NO975555L (no)	1995-06-07	1997-12-02	Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein

Country Status (18)

Country	Link
EP (2)	EP1090642B8 (2)
JP (2)	JP4233113B2 (2)
AT (2)	ATE400295T1 (2)
AU (1)	AU695720B2 (2)
BR (1)	BR9608612A (2)
CA (1)	CA2221511C (2)
CZ (1)	CZ390297A3 (2)
DE (2)	DE69637597D1 (2)
DK (1)	DK1090642T3 (2)
ES (2)	ES2164251T5 (2)
HU (1)	HUP9802199A3 (2)
IL (1)	IL122431A0 (2)
NO (1)	NO975555L (2)
NZ (1)	NZ311000A (2)
PT (1)	PT1090642E (2)
SI (1)	SI1090642T1 (2)
TR (1)	TR199701547T1 (2)
WO (1)	WO1996040242A1 (2)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6696065B1 (en)	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
NZ311000A (en) *	1995-06-07	1999-04-29	Smithkline Beecham Biolog	Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
AU714493B2 (en) *	1996-07-02	2000-01-06	Connaught Laboratories Limited	Multivalent DTP-polio vaccines
US6248334B1 (en)	1997-01-08	2001-06-19	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
CA2320470A1 (en) *	1998-02-05	1999-08-12	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
US7018637B2 (en) *	1998-02-23	2006-03-28	Aventis Pasteur, Inc	Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CA2366152A1 (en)	1999-03-19	2000-09-28	Smithkline Beecham Biologicals S.A.	Streptococcus pneumoniae vaccine
FR2806304B1 (fr) *	2000-03-17	2002-05-10	Aventis Pasteur	Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
CA2435681C (en)	2001-01-23	2011-06-21	Aventis Pasteur	Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) *	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
EP2351579B1 (en)	2002-10-11	2016-09-21	Novartis Vaccines and Diagnostics S.r.l.	Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
CA2503871C (en)	2002-11-01	2012-12-11	Glaxosmithkline Biologicals S.A.	An immunogenic composition for generating an immune response against polio virus
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
DK1587537T3 (da)	2003-01-30	2012-07-16	Novartis Ag	Injicerbare vacciner mod multiple meningococ-serogrupper
EP2210607B1 (en)	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
ES2397923T3 (es)	2003-10-02	2013-03-12	Novartis Ag	Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
GB0406013D0 (en)	2004-03-17	2004-04-21	Chiron Srl	Analysis of saccharide vaccines without interference
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
RU2379052C2 (ru)	2004-04-30	2010-01-20	Чирон С.Р.Л.	Вакцинация менингококковыми конъюгатами
GB0411387D0 (en)	2004-05-21	2004-06-23	Chiron Srl	Analysis of saccharide length
GB0413868D0 (en)	2004-06-21	2004-07-21	Chiron Srl	Dimensional anlaysis of saccharide conjugates
GB0428394D0 (en) *	2004-12-24	2005-02-02	Chiron Srl	Saccharide conjugate vaccines
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
GB0502096D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Purification of streptococcal capsular polysaccharide
GB0505518D0 (en)	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
EP1871411A4 (en)	2005-04-18	2010-07-21	Novartis Vaccines & Diagnostic	EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE
HUE045482T2 (hu)	2005-06-27	2019-12-30	Glaxosmithkline Biologicals Sa	Immunogén készítmény
CN102973929B (zh)	2005-09-01	2017-04-26	诺华疫苗和诊断有限两合公司	含血清群c脑膜炎球菌的多价疫苗
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
US10828361B2 (en)	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
NZ572054A (en)	2006-03-22	2011-12-22	Novartis Ag	Regimens for immunisation with meningococcal conjugates
SI2097102T1 (sl)	2006-09-07	2012-09-28	Glaxosmithkline Biolog Sa	Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
GB0700136D0 (en)	2007-01-04	2007-02-14	Glaxosmithkline Biolog Sa	Process for manufacturing vaccines
PT2349520T (pt)	2008-10-27	2016-08-16	Glaxosmithkline Biologicals Sa	Método de purificação para hidrato de carbono de estreptococos grupo a
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
US8974799B2 (en)	2009-09-30	2015-03-10	Novartis Ag	Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
PT2493498T (pt)	2009-10-30	2017-05-24	Glaxosmithkline Biologicals Sa	Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
EP2519265B1 (en)	2009-12-30	2018-11-14	GlaxoSmithKline Biologicals SA	Polysaccharide immunogens conjugated to e. coli carrier proteins
WO2012020326A1 (en)	2010-03-18	2012-02-16	Novartis Ag	Adjuvanted vaccines for serogroup b meningococcus
EP2612148B1 (en)	2010-09-04	2019-06-12	GlaxoSmithKline Biologicals SA	Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
US20130315959A1 (en)	2010-12-24	2013-11-28	Novartis Ag	Compounds
CN103533954B (zh)	2011-03-02	2015-09-09	诺华股份有限公司	含较低剂量的抗原和/或佐剂的联合疫苗
GB201106340D0 (en) *	2011-04-14	2011-06-01	Isis Innovation	Composition
EP2755683B1 (en)	2011-09-14	2019-04-03	GlaxoSmithKline Biologicals SA	Methods for making saccharide-protein glycoconjugates
RU2636350C2 (ru)	2011-11-07	2017-11-22	Новартис Аг	МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en)	2011-11-11	2013-05-15	Novartis AG	Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
GB201121301D0 (en)	2011-12-12	2012-01-25	Novartis Ag	Method
EP2822584A1 (en)	2012-03-08	2015-01-14	Novartis AG	Combination vaccines with tlr4 agonists
EP2852414B9 (en)	2012-05-22	2020-12-09	GlaxoSmithKline Biologicals SA	Meningococcus serogroup x conjugate
BR112015005056A2 (pt)	2012-09-06	2017-11-21	Novartis Ag	vacinas de combinação com sorogrupo b meningococcus e d/t/p
CN104582718B (zh)	2012-10-03	2017-10-24	诺华股份有限公司	免疫原性组合物
EP2906239A1 (en)	2012-10-12	2015-08-19	GlaxoSmithKline Biologicals SA	Non-cross-linked acellular pertussis antigens for use in combination vaccines
JP2016502994A (ja)	2012-12-18	2016-02-01	グラクソスミスクラインバイオロジカルズソシエテアノニム	ジフテリア及び／又は破傷風から防御するためのコンジュゲート
CA2897084C (en)	2013-01-04	2019-07-16	Cheng Der Tony Yu	Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
CN104174019A (zh) *	2014-09-23	2014-12-03	成都康华生物制品有限公司	四价脑膜炎球菌多糖载体蛋白结合疫苗
US9107906B1 (en)	2014-10-28	2015-08-18	Adma Biologics, Inc.	Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en)	2014-12-19	2016-06-22	Novartis AG	Purification of streptococcal capsular polysaccharide
WO2017175082A1 (en)	2016-04-05	2017-10-12	Gsk Vaccines S.R.L.	Immunogenic compositions
US11027005B2 (en)	2016-10-20	2021-06-08	Km Biologics Co., Ltd.	Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
US10259865B2 (en)	2017-03-15	2019-04-16	Adma Biologics, Inc.	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3799884A1 (en)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogenic compositions
US11173199B2 (en) *	2019-11-13	2021-11-16	Alopexx Inc.	Low contaminant compositions
WO2021174330A1 (en) *	2020-03-05	2021-09-10	Nuecology Biomedical Inc.	Amphiphilic alginate-oleic acid macromolecules and process for preparation therof
US20240000958A1 (en)	2020-11-13	2024-01-04	Glaxosmithkline Biologicals Sa	Novel carriers and conjugation methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4902506A (en) *	1983-07-05	1990-02-20	The University Of Rochester	Immunogenic conjugates
US4644059A (en) *	1982-07-06	1987-02-17	Connaught Laboratories, Inc.	Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
IT1187753B (it) *	1985-07-05	1987-12-23	Sclavo Spa	Coniugati glicoproteici ad attivita' immunogenica trivalente
RO111416B1 (ro) *	1989-12-14	1996-10-31	Ca Nat Research Council	Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
ZA937034B (en) *	1992-09-24	1995-06-23	Brigham & Womens Hospital	Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
ATE176157T1 (de) *	1992-10-27	1999-02-15	American Cyanamid Co	Pädiatrische kombinationsvakzine mit verbesserter immunogenizität jeder vakzine komponente
NZ311000A (en) *	1995-06-07	1999-04-29	Smithkline Beecham Biolog	Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein

1996
- 1996-06-04 NZ NZ311000A patent/NZ311000A/en unknown
- 1996-06-04 CA CA2221511A patent/CA2221511C/en not_active Expired - Lifetime
- 1996-06-04 DE DE69637597T patent/DE69637597D1/de not_active Expired - Lifetime
- 1996-06-04 HU HU9802199A patent/HUP9802199A3/hu unknown
- 1996-06-04 DK DK00203772T patent/DK1090642T3/da active
- 1996-06-04 AT AT00203772T patent/ATE400295T1/de active
- 1996-06-04 ES ES96920790T patent/ES2164251T5/es not_active Expired - Lifetime
- 1996-06-04 AU AU62221/96A patent/AU695720B2/en not_active Ceased
- 1996-06-04 JP JP50014697A patent/JP4233113B2/ja not_active Expired - Lifetime
- 1996-06-04 WO PCT/EP1996/002436 patent/WO1996040242A1/en not_active Ceased
- 1996-06-04 PT PT00203772T patent/PT1090642E/pt unknown
- 1996-06-04 EP EP00203772A patent/EP1090642B8/en not_active Revoked
- 1996-06-04 BR BR9608612A patent/BR9608612A/pt unknown
- 1996-06-04 SI SI9630763T patent/SI1090642T1/sl unknown
- 1996-06-04 EP EP96920790A patent/EP0831901B2/en not_active Expired - Lifetime
- 1996-06-04 DE DE69615362T patent/DE69615362T3/de not_active Expired - Lifetime
- 1996-06-04 IL IL12243196A patent/IL122431A0/xx unknown
- 1996-06-04 ES ES00203772T patent/ES2308962T3/es not_active Expired - Lifetime
- 1996-06-04 AT AT96920790T patent/ATE205724T1/de not_active IP Right Cessation
- 1996-06-04 CZ CZ973902A patent/CZ390297A3/cs unknown
- 1996-06-04 TR TR97/01547T patent/TR199701547T1/xx unknown
1997
- 1997-12-02 NO NO975555A patent/NO975555L/no unknown
2007
- 2007-03-12 JP JP2007061946A patent/JP4653131B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO1996040242A1 (en)	1996-12-19
ES2164251T3 (es)	2002-02-16
DE69637597D1 (de)	2008-08-21
EP0831901B1 (en)	2001-09-19
EP1090642B1 (en)	2008-07-09
JP2007186524A (ja)	2007-07-26
DE69615362D1 (de)	2001-10-25
AU6222196A (en)	1996-12-30
DE69615362T2 (de)	2002-06-13
DE69615362T3 (de)	2006-07-20
EP1090642B8 (en)	2010-08-11
ATE400295T1 (de)	2008-07-15
EP0831901A1 (en)	1998-04-01
DK1090642T3 (da)	2008-09-22
MX9709732A (es)	1998-10-31
CA2221511C (en)	2013-01-08
NO975555D0 (no)	1997-12-02
IL122431A0 (en)	1998-06-15
HUP9802199A1 (hu)	1999-01-28
HUP9802199A3 (en)	1999-07-28
ES2164251T5 (es)	2006-06-01
NZ311000A (en)	1999-04-29
BR9608612A (pt)	1999-05-04
EP1090642A2 (en)	2001-04-11
JPH11507026A (ja)	1999-06-22
ATE205724T1 (de)	2001-10-15
AU695720B2 (en)	1998-08-20
PT1090642E (pt)	2008-09-09
ES2308962T3 (es)	2008-12-16
CZ390297A3 (cs)	1998-05-13
SI1090642T1 (sl)	2008-12-31
JP4233113B2 (ja)	2009-03-04
EP0831901B2 (en)	2005-12-07
CA2221511A1 (en)	1996-12-19
EP1090642A3 (en)	2001-08-22
JP4653131B2 (ja)	2011-03-16
TR199701547T1 (xx)	1998-03-21

Publication	Publication Date	Title
NO975555D0 (no)	1997-12-02	Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein
EA199700413A1 (ru)	1998-08-27	Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия
ATE250937T1 (de)	2003-10-15	Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
PT1296711E (pt)	2006-08-31	E7 de vph para o tratamento do virus do papiloma humano
BRPI0114994B8 (pt)	2021-05-25	composição de vacina
WO1998055495A3 (en)	1999-05-27	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
YU47899B (sh)	1996-05-20	Postupak za dobivanje preparata koji sprečava prenošenje polnih bolesti i tampona koji ga sadrži
TR200001519T2 (tr)	2000-11-21	İnsanlardaki Spermatozoa'nın konsantrasyonu ve/veya hareket kabiliyetini artırmak için uygulanması gerekli yöntem ve ilaç terkipleri
BR0008076A (pt)	2002-02-05	16-hidroxiestratrienos como estrogênios de efeito seletivo
SE9400524L (sv)	1995-08-17	Energipreparat
NO955084L (no)	1996-02-14	Estrensteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
TR199700963T1 (xx)	1998-02-21	Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
HUP9801917A2 (hu)	1998-11-30	Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
AU3868895A (en)	1996-05-15	Process for the preparation of furosemide
IL117564A (en)	2005-03-20	Pharmaceutical and diagnostic compositions containing lysine derivatives
JUNG et al.	1997	Effect of total saponin on penile erection: a combined in vitro and in vivo study
王德深	1982	A PROPOSAL FOR THE INTERNATIONAL STANDARDIZATION OF THE NAMES OF ACUPUNCTURE POINTS
MD742C2 (ro)	1998-02-28	Remediu cu activitate regenerativă
陈德松 et al.	1995	QUADRILATERAL SPACE SYNDROME
RU94024812A (ru)	1996-05-10	Способ профилактики полиомиелита на крайнем севере